Recent 8-K filings for CDT

• August 21, 2026, 9:27 AM ET M&A materiality 0.70 neutral item 9.01

  CDT Equity files Sarborg acquisition financials: FY25 revenue $4.6M, net loss $508K, going concern risk

  Sarborg FY2025 revenue $4.626M vs $98K in 2024 (inception Oct 28, 2024); net loss $508K vs $282K.

• August 21, 2026, 9:27 AM ET M&A materiality 0.65 neutral item 2.01item 9.01item 1.01item 3.02

  CDT Equity files amended 8-K for Sarborg investment; Sarborg 2025 revenue $4.6M, net loss $508K

  Sarborg FY2025 revenue $4.6M, gross profit $4.2M, net loss $508K (vs. $98K revenue, $282K loss in 2024).

• August 6, 2026, 4:30 PM ET debt materiality 0.75 negative item 1.01item 2.03item 3.02item 9.01

  CDT Equity amends convertible note, principal to $2.54M, 19% interest, issues warrants

  Principal increased to $2,536,650 via second and third amendments; interest rate set at 19% per annum.

• July 31, 2026, 5:26 PM ET M&A materiality 0.80 neutral item 1.01item 3.02item 9.01

  CDT Equity acquires 4.76% stake in Sarborg; issues pre-funded warrants for 12.1M shares

  Acquired 270 shares of Sarborg (4.76% of outstanding) from investors in exchange for pre-funded warrants to purchase up to 12,131,770 shares of CDT common stock at $0.0001 per share.

• July 16, 2026, 8:05 AM ET other material materiality 0.60 negative item 3.03item 5.03item 7.01item 9.01

  CDT Equity announces 1-for-10 reverse stock split to comply with Nasdaq bid-price rule

  Reverse stock split effective July 17, 2026 at 5:00 pm ET; trading on split-adjusted basis July 20, 2026.

• June 29, 2026, 4:30 PM ET other materiality 0.75 negative item 4.01item 9.01

  CDT Equity dismisses auditor CBIZ CPAs, engages CRI; cites going concern, material weaknesses

  Audit committee dismissed CBIZ CPAs and engaged Carr, Riggs & Ingram (CRI) on June 23, 2026.

• June 16, 2026, 5:00 PM ET debt materiality 0.60 positive item 1.01item 2.03item 3.02item 8.01item 9.01 ◈ Material Agreements ×5◈ Debt Financings

  CDT Equity repays $6.3M legacy debt, enters new $1.46M JJ Astor loan

  Repaid $5,737,500 A.G.P. convertible loan notes and $555,556 Ascent Partners note, eliminating over $6.3M in legacy obligations.

• May 28, 2026, 4:30 PM ET regulatory materiality 0.70 negative item 3.01item 7.01item 9.01 ◈ Listing & Compliance Notices

  CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan

  Received Nasdaq deficiency notice on May 21, 2026 for failing to timely file Q1 2026 Form 10-Q under Listing Rule 5250(c)(1).

• March 25, 2026, 7:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 7.01item 9.01 ◈ Governance Changes

  CDT Equity Inc. announces 1-for-25 reverse stock split effective March 26, 2026

  Reverse stock split at 1:25 ratio; effective March 26, 2026 at 5:00 pm ET.

• March 18, 2026, 7:59 PM ET other material materiality 0.70 neutral item 5.07

  CDT Equity stockholders approve redomestication to Cayman Islands, reverse stock split, and share increase

  Redomestication from Delaware to Cayman Islands approved (Proposal 6): ~2.22M for, 72K against, 21.9K abstain.

• March 9, 2026, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03item 3.02item 9.01 ◈ Material Agreements ×2◈ Debt Financings

  CDT Equity lowers ELOC floor to $0.60 and issues $555K convertible note

  Amendment cuts ELOC floor price to $0.60; max shares issuable ~41.7M, subject to stockholder approval.

• February 24, 2026, 6:59 PM ET M&A materiality 0.75 neutral item 1.01item 3.02item 9.01 ◈ Equity Issuances ×5◈ Material Agreements ×3

  CDT Equity acquires 20% of Sarborg for stock, warrants, deferred $8M cash

  Acquired 1,020 Sarborg shares (~20% stake) in exchange for 598,006 shares + pre-funded warrants for 109,978,918 shares at $0.0001 exercise price.

• January 22, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 9.01 ◈ Equity Issuances◈ Material Agreements

  CDT Equity enters $25M equity line of credit with Ascent Partners; issues 204,031 commitment shares

  CDT Equity entered a directed stock purchase agreement for up to $25M of common stock with institutional investor Ascent Partners.

• December 12, 2025, 6:59 PM ET M&A materiality 0.75 negative item 1.01item 3.02item 9.01 ◈ Equity Issuances ×2◈ Material Agreements

  CDT sells CPL subsidiary to CEO affiliate Corvus for $7M to offload Strand litigation liability

  CDT sells CPL to Corvus Capital (wholly-owned by CEO Andrew Regan) for $7M in common stock or pre-funded warrants.

• August 14, 2025, 7:59 PM ET other material materiality 0.65 negative item 4.02 ◈ Auditor Changes

  CDT Equity restates Q1 2025 financials; $0.4M milestone misclassified as R&D

  On Aug 8, 2025, CDT Equity determined its unaudited Q1 2025 financials should no longer be relied upon.

• August 8, 2025, 7:59 PM ET other material materiality 0.65 neutral item 5.02item 5.03item 5.07item 7.01item 9.01 ◈ Governance Changes ×2

  Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan

  Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.

• May 6, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07

  Conduit Pharma stockholders approve reverse stock split up to 1-for-250 at special meeting

  Proposal passed with 5,065,868 votes for, 496,473 against, 1,438 abstentions.

• April 25, 2025, 7:59 PM ET other material materiality 0.70 negative item 4.01item 9.01 ◈ Auditor Changes ×2

  Conduit Pharmaceuticals changes auditor from Marcum to CBIZ CPAs; going concern and material weaknesses cited

  Marcum LLP resigned as independent auditor on April 24, 2025; CBIZ CPAs P.C. appointed on April 25, 2025.

• April 16, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01 ◈ executive_change

  Conduit Pharma appoints founder Andrew Regan as CEO; Tapolczay transitions to licensing role

  David Tapolczay resigned as CEO and board member effective April 12, 2025; to serve as Head of Licensing & Strategy at £240K salary.

• April 4, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02

  Conduit Pharmaceuticals enters AI analytics deal for AstraZeneca assets; issues 2.26M shares

  Entered additional agreement with Sarborg for AI analysis of AZD1656, AZD5658, AZD5904 clinical data to identify repurposing opportunities.

• April 2, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

  Conduit Pharmaceuticals regains full Nasdaq compliance after $8.3M raise and debt conversion

  Submitted pro-forma financials showing stockholder's equity of $2.8M vs $2.5M minimum required.

• April 1, 2025, 7:59 PM ET other materiality 0.65 positive item 8.01

  Conduit Pharmaceuticals provides Nasdaq compliance update; equity above $2.5M threshold

  Submitted pro-forma financials showing Stockholder's Equity of $2.8M as of March 31, 2025, above Nasdaq's $2.5M minimum.

• March 6, 2025, 6:59 PM ET regulatory materiality 0.65 neutral item 8.01

  Conduit Pharmaceuticals receives Nasdaq extension, plans transfer to Capital Market

  Nasdaq Hearing Panel granted extension to March 31, 2025 to regain MVPHS and MVLS compliance.

• February 19, 2025, 6:59 PM ET other material materiality 0.75 neutral item 1.02item 8.01item 3.01 ◈ Listing & Compliance Notices

  Conduit Pharmaceuticals repays $926k note, receives Nasdaq delisting basis for continued listing deficiencies

  Paid remaining $926,149 on Senior Note to Nirland Limited on Feb 13, 2025; all assets now free of liens.

• January 23, 2025, 6:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 7.01item 9.01 ◈ Governance Changes

  Conduit Pharmaceuticals announces 1-for-100 reverse stock split to meet Nasdaq bid price requirement

  Effective Jan 24, 2025 at 5pm ET; shares begin trading on split-adjusted basis Jan 27 under ticker CDT.

• December 20, 2024, 6:59 PM ET regulatory materiality 0.85 negative item 3.01item 5.02item 5.07 ◈ Listing & Compliance Notices

  Nasdaq notifies Conduit of delisting due to low price; shareholders approve reverse stock split

  Closing bid price ≤ $0.10 for 10 consecutive days; delisting set for Dec 27 unless hearing requested.

• November 25, 2024, 6:59 PM ET debt materiality 0.65 negative item 1.01item 2.03item 3.02item 9.01

  Conduit Pharma issues $5.74M convertible note to A.G.P. and amends Nirland note; conversion needs stockholder approval

  Issued $5,737,500 convertible note to A.G.P. for deferred commission; 5.5% interest, matures Nov 25, 2025.

• November 1, 2024, 7:59 PM ET debt materiality 0.65 negative item 1.01item 1.02item 2.03item 3.02item 9.01

  Conduit Pharmaceuticals secures $1.2M in new loans; issues warrants and amends existing debt

  Entered Bridge Loan with A.G.P. for up to $600k at 4.21% due Dec 31, 2024; issued warrants for 2.86M shares at $0.1048 per share, subject to shareholder approval.

• August 16, 2024, 7:59 PM ET other material materiality 0.85 negative item 3.01item 8.01

  Conduit Pharmaceuticals receives Nasdaq delisting notices; discloses 31% of shares pledged without company knowledge

  Nasdaq notified Conduit on Aug 15, 2024 for non-compliance: MVPHS <$15M and MVLS <$50M; 180-day cure period until Feb 11, 2025.

• August 8, 2024, 7:59 PM ET other material materiality 0.80 positive item 1.01item 3.02item 9.01

  Conduit licenses three AstraZeneca assets for autoimmune and infertility; issues 9.5M shares

  Exclusive license from AstraZeneca for HK-4 glucokinase activators AZD1656, AZD5658 and MPO inhibitor AZD5904.

• August 7, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 3.02item 9.01

  Conduit Pharmaceuticals issues $2.65M secured note at 12%, 12.5M shares to Nirland

  Senior Secured Promissory Note of $2,650,000 (incl. $500,000 OID), 12% interest, matures Aug 5, 2025.

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

6 positive 13 negative 31 neutral

source · CDT on sec.gov